ASH 2016 Highlights

CAR T-Cell Therapy Succeeds in Aggressive Lymphoma

By Phoebe Starr

ASH 2016 Highlights

February 2017, Vol 7, No 2

Obinutuzumab Prolongs Survival in Follicular Lymphoma

By Phoebe Starr

ASH 2016 Highlights

February 2017, Vol 7, No 2

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

By Wayne Kuznar

ASH 2016 Highlights

February 2017, Vol 7, No 2

Triplet Therapy That Includes Elotuzumab Stops Progression of High-Risk Smoldering Multiple Myeloma

By Wayne Kuznar

ASH 2016 Highlights, Multiple Myeloma, Hematologic Malignancies

February 2017, Vol 7, No 2

Strategies to Reduce the Use of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia

By Phoebe Starr

ASH 2016 Highlights

February 2017, Vol 7, No 2

R-CHOP Prevails Over Dose-Adjusted EPOCH-R as Standard of Care for Diffuse Large B-Cell Lymphoma

By Phoebe Starr

ASH 2016 Highlights

February 2017, Vol 7, No 2

New Value Model Incorporates Long-Term Adverse Effects of Cancer Drugs

ASH 2016 Highlights

February 2017, Vol 7, No 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

OPM Print Edition

OPM Weekly e‑Newsletter

I have reviewed and consent to the terms of OPM's Privacy Policy, and OPM has my permission to retain my information in its database, and to forward pertinent communications to me.